The WHO recommends that pfhrp2 deletion be explored in symptomatic individuals presenting to a healthcare facility whose infection fits the following criteria: microscopy positive (especially high density infections), HRP2 RDT negative and ideally Pf-pLDH RDT positive [28]. This evidence concerns the gene HDGFL2 and infection.